Research & Development - Stevanato Group
search img

R&D is a fundamental asset in the growth of Stevanato Group, which invests in it about 4% of its turnover, each year. R&D also represents a dimension of Stevanato Group’s vision, allowing it to evolve from a packaging component and automated equipment supplier to a global drug-delivery-systems strategic partner with a full-service approach to bio-pharmaceutical companies.

Being involved in the customer’s drug development process from an early stage, Stevanato Group can deliver science-based innovation through various services, including:

  • Clinical, laboratory and registration services with its laboratories and Technology Excellence Center, such as the one to be opened in Boston, Massachusetts in 2020
  • High-quality product development, including in-depth risk analysis to ensure a standardized project execution process
  • Definition of new proof of concept with rapid prototyping and engineering especially for the optimization of customer’s filling process, automation and robotic in device assembly and testing, assembly of components, and inspection
  • Advanced technical customer support benefiting from experts in the field of materials science (such as glass, plastics, polymers, coating, rubbers, and proteins), chemical, mechanical engineering and medical devices
  • Generation of technical and regulatory documentation fully compliant with global regulations such as those of the US FDA, China FDA, and EMA
services for pharma macro trends

How Stevanato Group responds to industry macro trends

Stevanato Group’s latest solutions are designed to meet both the most complex productivity and flexibility needs of biopharmaceutical companies and patient safety and quality of life. On the one hand, they focus on the continuous improvement of the EZ-fill® glass containers platform for a simplified supply chain and a reduction in the total cost of ownership for pharmaceutical companies. For this requirement, the answer is represented by the Alba® EZ-fill® platform for biological drugs and by the whole range of Nexa® containers, which are ideal for integration into drug delivery systems.

On the other hand, leveraging on its glass primary packaging, precise injection molded plastics and assembly equipment, Stevanato Group has developed the Integrated Safety System (ISS), a safety device aimed at simplifying the patient self- administration process, while preventing needle stick injuries.
It is also developing drug delivery systems, such as its proprietary cartridge-based wearable device, a discreet and easy to wear wearable, which is activated by an electronic hand held to facilitate the monitoring of timing and administration processes, while containing the cost of healthcare.

logo stevanato group
linkedin facebook